Dimension Capital's $800M third fund shows the science-and-compute convergence thesis is printing money

From $500M to $800M in 18 Months: Dimension Capital's Science-Compute Bet Is Validating Faster Than Planned

Eighteen months. That is the gap between Dimension Capital's $500 million second fund and a third one that landed 60% larger.

The New York firm closed an $800 million third fund, announced a year and a half after its predecessor 1. While other newer VC firms still struggle to raise fresh capital, Dimension has now raised three progressively larger funds in under four years. Zavain Dar and Adam Goulburn, formerly partners at Lux Capital, and Nan Li, an Obvious Ventures alum, founded the firm in late 2022 with a specific prediction: deep-tech companies would increasingly blur the boundary between biotech and software 1. That thesis is not just working. It is validating faster than the people who bet on it expected 1.

Take Chai Discovery. Dimension co-led a $30 million seed in 2024. The startup, which develops open-source AI foundation models for drug development, announced the previous week that it had raised $400 million at a $3.8 billion valuation 1. Its website describes the product as "the computer-aided design suite for molecules," with named partners including Novartis, Pfizer, Eli Lilly, and argenx 2. A seed-to-billion trajectory in under two years. That growth curve looks like a software company, not a biotech one.

New Limit followed a similar arc. Dimension backed the anti-aging startup, co-founded by Coinbase CEO Brian Armstrong, at its Series A in January 2025. Earlier this month, New Limit completed a Series C at a $3.1 billion valuation 1. The company's platform uses AI to design payloads that reprogram aging cells to a youthful state, testing thousands of designs simultaneously and retraining on the results 3. Biotech and compute, fused into a single discovery engine. Exactly what Dimension underwrites.

But the clearest signal that the convergence thesis has arrived may have come from the buyer's side. This spring, Anthropic acquired Coefficient Bio, a Dimension-backed drug discovery platform, for a reported $400 million, with Dimension receiving Anthropic shares in the deal 1. An AI company buying drug discovery infrastructure is a strategic acknowledgment that the next frontier of compute runs through biology. The dissolution of the boundary between science and compute is no longer a prediction. It is an acquisition category. Dimension also counts inference company Modal Labs among its investments, reinforcing the thesis from both sides of the convergence 1.

For builders, the valuation trajectories carry a practical signal. The companies getting funded at premium valuations are the ones where AI is not a feature layered onto a biotech workflow but the core engine of discovery. Chai Discovery designs molecules computationally. New Limit uses machine learning to identify which transcription factors can reprogram cells. In both cases, the model is the product. That distinction is where capital is concentrating.

For investors, the signal is sharper and less comfortable. Dimension's partners have said they did not expect their thesis to play out this quickly 1. When the people who got in early are themselves surprised by the speed of validation, the entry window for everyone else has likely already narrowed. The spread between proven and speculative science-compute companies is widening fast, and the premiums are going to the few that have shown the model works.

An $800 million fund, 60% larger than the $500 million one that preceded it by 18 months, reflects a firm whose conviction is compounding. The harder question is what Dimension deploys it into next. The companies that proved the model are already priced in the billions. The ones that have not are still experiments. For a firm whose thesis is being validated faster than it planned, the next challenge is not proving the convergence. It is finding opportunities before the premiums erase the entry advantage.